Sionna Therapeutics (SION) Competitors $11.63 -0.35 (-2.92%) As of 01:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsTrendsBuy This Stock SION vs. CGON, DNLI, KYMR, TARS, ARQT, CNTA, ARWR, HRMY, TVTX, and JANXShould you be buying Sionna Therapeutics stock or one of its competitors? The main competitors of Sionna Therapeutics include CG Oncology (CGON), Denali Therapeutics (DNLI), Kymera Therapeutics (KYMR), Tarsus Pharmaceuticals (TARS), Arcutis Biotherapeutics (ARQT), Centessa Pharmaceuticals (CNTA), Arrowhead Pharmaceuticals (ARWR), Harmony Biosciences (HRMY), Travere Therapeutics (TVTX), and Janux Therapeutics (JANX). These companies are all part of the "pharmaceutical products" industry. Sionna Therapeutics vs. CG Oncology Denali Therapeutics Kymera Therapeutics Tarsus Pharmaceuticals Arcutis Biotherapeutics Centessa Pharmaceuticals Arrowhead Pharmaceuticals Harmony Biosciences Travere Therapeutics Janux Therapeutics CG Oncology (NASDAQ:CGON) and Sionna Therapeutics (NASDAQ:SION) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their community ranking, risk, analyst recommendations, earnings, valuation, institutional ownership, dividends, media sentiment and profitability. Does the MarketBeat Community favor CGON or SION? CG Oncology received 20 more outperform votes than Sionna Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Sionna Therapeutics an outperform vote while only 92.00% of users gave CG Oncology an outperform vote. CompanyUnderperformOutperformCG OncologyOutperform Votes2392.00% Underperform Votes28.00%Sionna TherapeuticsOutperform Votes3100.00% Underperform VotesNo Votes Which has higher valuation and earnings, CGON or SION? Sionna Therapeutics has lower revenue, but higher earnings than CG Oncology. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCG Oncology$684K2,902.45-$48.61MN/AN/ASionna TherapeuticsN/AN/AN/AN/AN/A Do insiders and institutionals have more ownership in CGON or SION? 26.6% of CG Oncology shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Do analysts rate CGON or SION? CG Oncology currently has a consensus price target of $63.88, indicating a potential upside of 144.65%. Sionna Therapeutics has a consensus price target of $38.50, indicating a potential upside of 226.83%. Given Sionna Therapeutics' higher possible upside, analysts plainly believe Sionna Therapeutics is more favorable than CG Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CG Oncology 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 3.10Sionna Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is CGON or SION more profitable? Sionna Therapeutics has a net margin of 0.00% compared to CG Oncology's net margin of -10,642.98%. Sionna Therapeutics' return on equity of 0.00% beat CG Oncology's return on equity.Company Net Margins Return on Equity Return on Assets CG Oncology-10,642.98% -18.97% -15.36% Sionna Therapeutics N/A N/A N/A Does the media prefer CGON or SION? In the previous week, CG Oncology had 7 more articles in the media than Sionna Therapeutics. MarketBeat recorded 15 mentions for CG Oncology and 8 mentions for Sionna Therapeutics. CG Oncology's average media sentiment score of 0.80 beat Sionna Therapeutics' score of -0.15 indicating that CG Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CG Oncology 4 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sionna Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Neutral SummaryCG Oncology beats Sionna Therapeutics on 8 of the 13 factors compared between the two stocks. Remove Ads Get Sionna Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SION and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SION vs. The Competition Export to ExcelMetricSionna Therapeutics IndustryMedical SectorNASDAQ ExchangeMarket Cap$501.75M$2.74B$5.63B$7.89BDividend YieldN/A13.10%4.57%4.01%P/E RatioN/A11.7723.1218.72Price / SalesN/A2,441,780.62384.2791.12Price / CashN/A16.2238.1634.64Price / BookN/A2.976.884.24Net IncomeN/A$46.61M$3.20B$247.06M7 Day Performance-13.81%-0.82%-2.57%-1.72%1 Month Performance-14.31%-2.32%1.95%-5.34%1 Year PerformanceN/A1.99%9.80%-0.38% Sionna Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SIONSionna TherapeuticsN/A$11.70-2.3%$38.50+229.1%N/A$497.50MN/A0.0035CGONCG Oncology1.2428 of 5 stars$26.54-3.6%$63.88+140.7%-34.3%$2.02B$684,000.000.0061Earnings ReportAnalyst ForecastDNLIDenali Therapeutics4.4376 of 5 stars$13.81-2.2%$37.20+169.4%-31.6%$2.01B$330.53M-5.00430Positive NewsKYMRKymera Therapeutics1.3903 of 5 stars$30.39-4.5%$56.36+85.4%-24.8%$1.97B$47.07M-12.99170Positive NewsTARSTarsus Pharmaceuticals2.2563 of 5 stars$51.01-0.6%$63.67+24.8%+46.5%$1.96B$182.95M-13.3950Insider TradeARQTArcutis Biotherapeutics2.5565 of 5 stars$16.47-3.7%$18.80+14.1%+67.8%$1.95B$196.54M-9.20150Short Interest ↓CNTACentessa Pharmaceuticals3.1562 of 5 stars$14.54-8.0%$26.00+78.8%+30.7%$1.92B$6.85M-9.50200Earnings ReportAnalyst ForecastInsider TradeAnalyst RevisionNews CoverageHigh Trading VolumeARWRArrowhead Pharmaceuticals3.4679 of 5 stars$13.93-5.4%$41.44+197.5%-51.9%$1.91B$2.50M-2.69400HRMYHarmony Biosciences4.4741 of 5 stars$33.21+0.7%$53.33+60.6%-0.5%$1.90B$714.73M15.74200TVTXTravere Therapeutics2.7921 of 5 stars$20.79-1.0%$30.62+47.3%+165.6%$1.84B$233.18M-5.07460News CoveragePositive NewsJANXJanux Therapeutics2.6302 of 5 stars$30.12-2.3%$92.44+206.9%-21.5%$1.82B$10.59M-25.7430Positive News Remove Ads Related Companies and Tools Related Companies CGON Alternatives DNLI Alternatives KYMR Alternatives TARS Alternatives ARQT Alternatives CNTA Alternatives ARWR Alternatives HRMY Alternatives TVTX Alternatives JANX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SION) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredTrump’s Treasure Map [Pic inside]We were shown this map by former Presidential Advisor, Jim Rickards, one of the most politically connected men...Paradigm Press | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sionna Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sionna Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SION Stock Free SION Stock Alerts